Clinical trial
Insulin Glulisine, Diabetes Mellitus Type 1
NCT00397553 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00397553 |
|---|---|
| Title | Insulin Glulisine, Diabetes Mellitus Type 1 |
| Official title | Multicenter, Open, Non-randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | Insulin glulisine |
| Enrollment | 104 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2007 |
| First posted | Nov 9, 2006 |
| Last update posted | Sep 18, 2009 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: